PMEF
AKRO

Point72 Middle East FZE’s Akero Therapeutics AKRO Stock Holding History

Point72 Middle East FZE’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-124
Closed -$4.74K – 1506
2023
Q1 		$4.74K Buy
+124
New +$5.53K ﹤0.01% 1523

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Middle East FZE's AKRO Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Akero Therapeutics (AKRO) in Q2 2023, closing a stake of 124 shares — an estimated $4.74K sold.

Point72 Middle East FZE first reported a position in AKRO in Q1 2023 and held it in 1 quarter. The position peaked at $4.74K in Q1 2023. 157 funds tracked by Wall St. Rank hold AKRO as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Akero Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 124 Akero Therapeutics shares in Q2 2023, an estimated $4.74K.
  • Point72 Middle East FZE first reported a position in Akero Therapeutics in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Akero Therapeutics position peaked at $4.74K in Q1 2023.
  • 157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.